Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Fiche du document

Auteurs
Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/hiv.13561

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37816492

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-1293

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_5750616518283

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/

Mots-clés 0

Humans; Tenofovir/therapeutic use; Hepatitis B Surface Antigens/therapeutic use; Antiviral Agents/therapeutic use; Cohort Studies; HIV Infections/drug therapy; Hepatitis B, Chronic/drug therapy; Hepatitis B e Antigens/therapeutic use; DNA, Viral; HBsAg; HIV; hepatitis B; tenofovir; trajectories

Sujets proches En

Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases

Citer ce document

L. Begré et al., « Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. », Serveur académique Lausannois, ID : 10.1111/hiv.13561

Métriques

Partage / Export

Résumé 0

Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study. We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets